Ask AI
Back Back
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Peter Lio
Peter Lio, MD, FAAD
Activity Information

Activity

Progress
1
Course Completed

Case History and Presentation 
Anna, a 25-year-old woman, presents with a history of AD that began during first few months of life. Initially, her symptoms were managed with intermittent use of over-the-counter emollients and mild topical corticosteroids. However, over time, the disease has become more persistent and severe, requiring high-potency topical corticosteroids and daily emollients as part of her regimen. Despite these efforts, the past 2 years have seen a worsening of her condition, marked by persistent itching, scaling, and recurrent flares. Anna’s symptoms significantly disrupted her quality of life, interfering with her sleep, productivity at work, and social interactions. She has tried phototherapy in the past with no improvement in her condition and expresses frustration over the inability of the treatments to provide lasting relief. 

Current clinical presentation:

  • EASI score: 28
  • Body surface area involvement: 17% 
  • Itch Numeric Rating Scale score: 8/10 
  • Other considerations: Anna reports no history of serious infections or chronic illnesses. She has no contraindications to systemic therapies and expresses willingness to explore advanced treatment options. 

Anna asks her dermatologist about advanced treatment options to better manage her symptoms.  

Based on Anna’s clinical presentation, what would be the most appropriate next step in management?